Antihistamines enhance immunotherapy

[jack14]

Antihistamines can influence immunotherapy response by enhancing T cell activation
by University of Texas M. D. Anderson Cancer Center

Would you like to receive trending story notifications on your smartphone?


Credit: Pixabay/CC0 Public Domain
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors. The preclinical study demonstrated that the histamine receptor H1 (HRH1) acts in tumor-associated macrophages (TAMs) to suppress T cell activation in the tumor microenvironment. The findings were published today in Cancer Cell.

CFTR Assay
Provides the broadest coverage
Streamlined PCR + CE workflow.
asuragen.com
OPEN


If replicated in prospective clinical trials, the data suggest that targeting HRH1 may be useful as a treatment approach in combination with checkpoint blockade to overcome immunotherapy resistance and improve outcomes, particularly for patients with pre-existing allergies or high plasma histamine levels.
"In searching for factors that might influence responses to immunotherapy, we were surprised to discover that antihistamines, a mediator of the allergy response, were associated with significantly improved outcomes in patients," said study co-lead Yi Xiao, Ph.D., instructor of Molecular & Cellular Oncology. "Looking closer at this relationship, we discovered that histamine, through its receptor HRH1, can promote cancer cell immune evasion and resistance to immunotherapy."
Antihistamines associated with improved immunotherapy outcomes
Immune checkpoint inhibitors, a type of immunotherapy, work by blocking certain checkpoint proteins that regulate the activity of T cells, unleashing the T cells to mount an anti-tumor response and eliminate cancer cells. Checkpoint blockade provides long-lasting responses for many patients, but not all benefit equally. Therefore, there is a desire to better understand factors that contribute to immunotherapy sensitivity or resistance.
This study began with the researchers investigating if other commonly used medications might influence responses to checkpoint inhibitors. They performed a retrospective analysis of clinical data from MD Anderson patients undergoing treatment with immune checkpoint inhibitors.
In those with melanoma or lung cancer, concurrent use of antihistamines targeting HRH1 was correlated with significantly improved survival outcomes. Patients with breast or colon cancer also displayed similar trends, although the data did not reach statistical significance due to a relatively small sample size.

[jack14]

I found this interesting. I plan to ask my oncologist next month if she thinks I might benefit. I avoid antihistamines like Benadryl and Sudafed because they mess with my bladder function (probably my bph). But I believe that the second and third generations of antihistamines like Claritin have less side effects. I also have stage 3 CKD. 

[LexieCat]

Do you have a link to that article, Jack? Thanks for sharing it.

[jack14]

16 hours ago, LexieCat said:

Do you have a link to that article, Jack? Thanks for sharing it.

Does this help?

NEWS RELEASE 24-NOV-2021

Antihistamines can influence immunotherapy response by enhancing T cell activation

Study uncovers new role for histamine receptor, suggesting possible treatment approach in combination with checkpoint inhibitors

Peer-Reviewed Publication

UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER

PrintEmail App

 

IMAGE: DIHUA YU, M.D., PH.D. view more 

CREDIT: MD ANDERSON CANCER CENTER

HOUSTON ― New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors. The preclinical study demonstrated that the histamine receptor H1 (HRH1) acts in tumor-associated macrophages (TAMs) to suppress T cell activation in the tumor microenvironment. The findings were published today in Cancer Cell.

If replicated in prospective clinical trials, the data suggest that targeting HRH1 may be useful as a treatment approach in combination with checkpoint blockade to overcome immunotherapy resistance and improve outcomes, particularly for patients with pre-existing allergies or high plasma histamine levels.

“In searching for factors that might influence responses to immunotherapy, we were surprised to discover that antihistamines, a mediator of the allergy response, were associated with significantly improved outcomes in patients,” said study co-lead Yi Xiao, Ph.D., instructor of Molecular & Cellular Oncology. “Looking closer at this relationship, we discovered that histamine, through its receptor HRH1, can promote cancer cell immune evasion and resistance to immunotherapy.”

 

Antihistamines associated with improved immunotherapy outcomes

Immune checkpoint inhibitors, a type of immunotherapy, work by blocking certain checkpoint proteins that regulate the activity of T cells, unleashing the T cells to mount an anti-tumor response and eliminate cancer cells. Checkpoint blockade provides long-lasting responses for many patients, but not all benefit equally. Therefore, there is a desire to better understand factors that contribute to immunotherapy sensitivity or resistance.

This study began with the researchers investigating if other commonly used medications might influence responses to checkpoint inhibitors. They performed a retrospective analysis of clinical data from MD Anderson patients undergoing treatment with immune checkpoint inhibitors.

In those with melanoma or lung cancer, concurrent use of antihistamines targeting HRH1 was correlated with significantly improved survival outcomes. Patients with breast or colon cancer also displayed similar trends, although the data did not reach statistical significance due to a relatively small sample size.

Using The Cancer Genome Atlas and other publicly available patient cancer data, the team also discovered that high expression of HRH1 in tumors was correlated with markers of T cell dysfunction, poor responses to checkpoint inhibitors and poorer survival outcomes.
 

Histamine receptor acts in tumor microenvironment to suppress T cell activation

Following the correlations observed, the researchers sought to clarify the possible contributions of HRH1 and its ligand, histamine, to the immune response.

They discovered both proteins were elevated in the tumor microenvironment, but they did not appear to come from the same source. HRH1 was not present in cancer cells but was highly expressed in certain types of TAMs in the tumor microenvironment, known as M2-like macrophages, that contribute to immune suppression. Conversely, cancer cells appear to be a major source of increased histamine levels in patient samples and cancer cell lines.

In preclinical models, blocking HRH1 on macrophages — either by genetic knockout or antihistamine treatment — decreased the immune-suppressive activity of the TAMs, leading to increased T cell activation and inhibition of tumor growth.

To understand how HRH1 in TAMs influences T cell activity, the researchers looked at additional regulatory receptors on the macrophages. Blocking HRH1 activity reduced the membrane localization of VISTA, an inhibitory receptor known to suppress T cell activation. Further, blocking HRH1 caused broad changes in gene expression, resulting in a shift from M2-like features to a more pro-inflammatory state consistent with M1-like macrophages.

The mechanistic data demonstrated that HRH1 acts in TAMs to drive cells toward an immune-suppressive M2-like state and to increase membrane expression of the inhibitory checkpoint VISTA, ultimately leading to dysfunctional T cells and a suppressed anti-tumor response.

 

Targeting HRH1 enhances checkpoint blockade responses in preclinical models

In preclinical models of breast cancer and melanoma, combining an antihistamine with checkpoint blockade enhanced therapeutic efficacy and prolonged survival over checkpoint blockade alone. Additionally, the antihistamine achieved similar responses in preclinical models as treatment with anti-VISTA antibodies, which are currently being evaluated in clinical trials.

Further, the researchers used a preclinical model of allergic disease to investigate the effects on tumor progression. After allergies were induced, histamine levels and tumor growth increased relative to controls. However, these effects could be reversed with antihistamine treatment.

Similarly, the researchers demonstrated a correlation between plasma histamine levels in patients with cancer and responses to immune checkpoint inhibitors. These findings suggest that elevated histamine levels, either from allergies or cancer cell production, may contribute to suppression of the anti-tumor response.

“Our preclinical findings suggest that antihistamines have the potential to enhance responses to immunotherapy, especially in those with high levels of histamine in the blood,” said corresponding author Dihua Yu, M.D., Ph.D., chair ad interim of Molecular & Cellular Oncology. “There is more work to be done, but we are excited to continue exploring possible therapeutic applications with antihistamines, which offer an inexpensive approach with minimal side effects.”

Moving forward, the team is working to design prospective clinical trials to evaluate the combination of antihistamines and checkpoint inhibitors in patients with cancer.

This research was supported by the National Institutes of Health (R01CA112567, R01CA184836, R01CA208213, and P30CA016672), the Cancer Prevention & Research Institute of Texas (CPRIT) (RP180734) and grants from METAvivor.

A full list of collaborating authors can be found with the full paper here. The authors have no conflicts of interest.

- 30 -

[jack14]

https://medicalxpress.com/news/2021-11-antihistamines-immunotherapy-response-cell.html

[LexieCat]

Thanks very much, Jack! I passed the link to my oncologist to discuss next week. I found it especially interesting since a lot of my coughing seems related to sinus/nasal mucus--I'm blowing my nose a lot. The steroids do seem to be helping with the cough and SoB. Anyway, if antihistamines also helped with the immunotherapy (I know steroids work against it), it seems like it might be worth a try.

[LexieCat]

Just got message from my oncologist, who found the article very interesting. She wasn't sure yet how to translate that into clinical practice, but she said we'd talk about it next week.

 

[Tom Galli]

Jack,

Good show posting this paper. It might be very helpful going forward. 

Stay the course. 

Tom

[Judy M2]

There is also a theory that loratadine (Claritin) may improve efficacy of Tagrisso. I take it every day anyway for nasal allergies/post-nasal drip caused by Tagrisso. 

[jack14]

It sounds encouraging to me. Could explain why some folks fail to see NED or at least a positive response. I have had 27 Keytruda infusions and seen “ no progression” but no NED or shrinkage.

After reading this, I think that my chronic inflammation in my abdomen as well as chronic sinusitis, might be creating histamine and interfering with the immunotherapy.

Does that make sense?

[LexieCat]

My oncologist said I could go ahead and try an antihistamine as an adjunct to my immunotherapy (Tecentriq)--she just emailed me that drugs in the class mentioned included Zyrtec, Claratin, and Allegra. This article, which discusses the MD Anderson article, also mentions those three. https://www.genengnews.com/news/2nd-gen-antihistamine-drugs-may-improve-outcomes-for-cancer-patients-receiving-immunotherapy/

Just a reminder to anyone on the Forums--be sure your oncologist knows about (and approves) any medications you are taking--including OTC meds like these.

[jack14]

I saw my oncologist and she was impressed with the study. She told me that she had attended a conference at MD Anderson and had a lot of respect for them, She also said that Claritin 10 mg day would be a good one to try. Zyrtec was also mentioned.
 

I asked her about trying the pediatric dose because of my kidney disease and bph. She advised me to take the adult dose and stop if I had any issues.

I took my first dose earlier today and so far so good.

Edited December 4, 2021 by jack14
Error

[jack14]

It’s 10mg of Claritin per day , not 20. Anyway, so far I haven’t had any problems. In fact I think my urinary issues are resolved!

[LouT]

Jack,

You're running your own "mini trial" I'm interested in hearing how this all works out.  Best of all luck my friend.

Lou

[jack14]

Thank you, you count on that Lou! I definitely intend to keep all of you guys informed. Not sure exactly when I am due a serial CT scan, but I suspect soon. I sure hope that it helps. Anyway, so far so good. I don’t have that chronic rhinitis that I have suffered forever. The CT scans have also confirmed the presence of congestion in my sinuses.

In the meantime, I urge everyone who is on immunotherapy to ask their oncologists if it would be ok to begin this regimen too. Everything to gain, little risk.

[Good Bro]

My brother will be discussing this with his oncologist this week.  I made the recommendation to him after reading about it on this forum.  Thank you to all.  

Brother is having very little response to his treatments.  Some evidence of positive response but also some progression (spread to liver).   

[jack14]

My best wishes for a turnaround.